Personalized medicine: biomarkers and companion diagnostics

Renato Bernardini, Giovanni Gancitano, Angela Balice, Rosaria Di Mauro, Giuseppina Cantarella, Matteo Dionisi

DOI: https://doi.org/10.7175/fe.v19i1.1348

Abstract

Great expectations are bound to the current evolution of medicine to personalized medicine. Thanks to rapid advances in genomics and molecular biology, new markers can be revealed for the presence of or susceptibility to a disease, or response to treatment. On such markers, diagnostic tests can be based; companion diagnostics (CDx, often called In Vitro devices) are diagnostic tests “coupled” with a therapeutic drug, aimed at assessing its applicability to a specific class of patients. As well as exemplifying some already implemented CDx applications, the purpose of this article is to highlight potentials and problems of personalized medicine today. In particular, the opportunity is analyzed for the co-development of a new drug and its CDx, through a parallel base research. This approach is promoted by the regulatory agencies but, due to scientific and economic factors implicit in the process, it is taking-off slowly. Personalized medicine deserves to grow and to expand, first of all because it simultaneously promises to substantially improve patient care and to make big costs savings for healthcare systems. From this point of view, all stakeholders (diagnostics manufacturers, clinical testing laboratories, pharmaceutical firms, the Department of health, and other bodies) should talk to each other in order to support the advancement of personalized medicine.

Keywords

Personalized medicine, Companion diagnostics, Biomarkers

Full Text:

HTML PDF

References

  • European Commission 25.10.2013 SWD(2013) 436 final: Commission staff working document: Use of ‘-omics’ technologies in the development of personalised medicine. Available at https://ec.europa.eu/research/health/pdf/2013-10_personalised_medicine_en.pdf (last accessed December 2017)
  • President’s Council of Advisors on Science and Technology. Priorities for Personalized Medicine. September 2008. Available at https://www.hsdl.org/?view&did=234678 (last accessed December 2017)
  • Rodriguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer Treatment. J Intern Med 2015; 277: 201-17; https://doi.org/10.1111/joim.12321
  • Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche COBAS® EGFR mutation test v2 for non-small cell lung cancer. Expert Review of Molecular Diagnostics 2017; 17: 209-15; https://doi.org/10.1080/14737159.2017.1288568
  • Thorne-Nuzzo T, Williams C, Catallini A, et al. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Onco 2016; 12: 804-13; https://doi.org/10.1016/j.jtho.2017.01.020
  • U.S. Food & Drug Administration. Companion Diagnostics. Available at https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407297.htm (last accessed December 2017)
  • Donovan MJ, Cordon-Cardo C. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. Mol Diagn Ther 2017; 21: 115-23; https://doi.org/10.1007/s40291-016-0249-5
  • European Medicines Agency. Concept paper on predictive biomarker-based assay development in the context of drug development and lifecycle. 2017. EMA/CHNP/800914/2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/07/WC500232420.pdf (last accessed December 2017)
  • Degeling K, Koffijberg H, IJzerman MJ. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 17-25; https://doi.org/10.1080/14737167.2017.1273110
  • Wulfkuhle JD, Spira A, Edmiston KH, et al. Innovations in Clinical Trial Design in the Era of Molecular Profiling.- Molecular Profiling: Methods and Protocols, Methods in Molecular Biology. Vol 1606. New York: Humana Press, 2017
  • Dearden S, Brown H, Jenkins S, et al. EGFR T790M mutation testing within the osimertinib AURA Phase I study. Lung Cancer 2017; 109; 9-13; https://doi.org/10.1016/j.lungcan.2017.04.011
  • Cheng MM, Palma JF, Scudder S, et al. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med 2017; 7; https://doi.org/10.3390/jpm7030005
  • Luo D, Smith JA, Meadows NA. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics. Front Genet 2016; 6: 357; https://doi.org/10.3389/fgene.2015.00357
  • Tímár J, Ladányi A. Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing. Magy Onkol 2017; 61: 158-66
  • Nagy Z. Biomarkers in solid tumors. Magy Onkol 2013; 57: 56-62
  • Berry DA. The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol 2015; 9: 951-9; https://doi.org/10.1016/j.molonc.2015.02.011
  • Nenadić I, Staber J, Dreier S, et al. Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers 2017; 9: 88; https://doi.org/10.3390/cancers9070088
  • Brüggenjürgen B, Kornbluth L, Ferrara JV, et al. Clinical and health economic challenges of personalized medicine. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55: 710-4; https://doi.org/10.1007/s00103-012-1479-2
  • Renfro LA, An M-W, Mandrekar SJ. Precision oncology: A new era of cancer clinical trials. Cancer Lett 2017; 387: 121-6; https://doi.org/10.1016/j.canlet.2016.03.015

Refbacks

  • There are currently no refbacks.




© SEEd srl